Tag Archives: Stephen Schultz

GWPH Phase 3 Results

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex (cannabidiol) Data Released by the American Academy of Neurology

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex (cannabidiol) Data Released by the American Academy of Neurology

LONDON, April 18, 2017 /Weed Wire/ – GW Pharmaceuticals noted that the American Academy of Neurology (AAN) issued a press release today announcing positive results from a second Phase 3 study (GWPCARE3) of Epidiolex.

GWPH Phase 3 Results

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma

LONDON, Feb. 7, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

LONDON, Sept. 26, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

LONDON, Sept. 7, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference.

GWPH Phase 3 Results

GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress

LONDON, Aug. 9, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the third quarter ended 30 June 2016.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

LONDON, June 27, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”) announces positive results of the first randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

GWPH Phase 3 Results

GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)

LONDON, June 21, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq: GWPH) (AIM: GWP) (“GW” or “the Company”) today announced that the Company has selected infantile spasms (IS) as the fourth target indication for its Epidiolex orphan pediatric epilepsy development program.

GWPH Phase 3 Results

GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress

LONDON, May 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (AIM:GW) (the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the second quarter and half-year ended 31 March 2016.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference on 10 May

LONDON, May 4, 2016 /Weed Wire/ — GW Pharmaceuticals announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10, 2016, at 9:20 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev.

Epidiolex in Utah

Epidiolex in Utah: Decrease in Seizure Frequency and Severity

In September 2014, The University of Utah’s Division of Pediatric Neurology and Primary Children’s Medical Center started the first of three clinical trials on the efficacy of Epidiolex, a nonpsychoactive cannabidiol-based drug from GW Pharmaceuticals (NASDAQ: GWPH).

GWPH Phase 3 Results

GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex

LONDON, April 11, 2016 /Weed Wire/ — GW Pharmaceuticals plc today announced that it has commenced a Phase 3 clinical trial of Epidiolex® (cannabidiol or CBD) as an adjunctive therapy for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic disorder, the most common symptom of which is epilepsy.


Top